B Braun Medical recalled 10,896 IV administration sets on October 29, 2025. The recall addresses a risk of medication backflow from secondary IV containers. This issue could lead to serious health risks for patients.
Potential for backflow of medication from secondary (piggyback) IV containers into primary IV containers and the inability to prime (occlusion).
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact B Braun Medical Inc or your healthcare provider for instructions. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled IV administration sets include the model labeled as IV ADMIN SET W/CARESITE EXT SET; Catalog Number: 490407. These products have a Primary UDI-DI of 04046964773242 and a Unit of Dose UDI-DI of 04046964773235. The affected devices were distributed worldwide, including the US, Canada, Germany, Guatemala, and Singapore.
The recall stems from a potential backflow of medication from secondary IV containers into primary IV containers. Additionally, there is an inability to prime due to occlusion, which poses a high risk to patient safety.
While specific incident counts were not reported, the hazard presents a high risk of serious health complications. Improper medication delivery can result in adverse health effects for patients receiving intravenous therapy.
Patients and healthcare providers must stop using the recalled IV administration sets immediately. Follow the manufacturer's recall instructions and contact B Braun Medical Inc or your healthcare provider for further guidance.
For more information, contact B Braun Medical Inc at 1-800-xxx-xxxx or visit their website. Additional details are also available on the FDA recall page.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.